ReviewCancer management and research2026
Digital Health in Pediatric Oncology and Hematooncology: A Quasi-Systematic Review of Telehealth, mHealth and Precision Medicine.
Review in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pediatric oncological and hematological diseases remain a significant challenge due to their complexity, the need for personalized treatment, and long-term follow-up. Recent advances in medical technologies, particularly in information technology (IT), telemedicine, mobile health (mHealth), and precision medicine, have opened new possibilities for improving care and supporting clinical decision-making in pediatric patients. This quasi-systematic review examines the current landscape of emerging technologies applied in pediatric oncology and hematology. A structured literature search was conducted in MEDLINE (PubMed), Web of Science, Scopus, and Google Scholar between March and April 2024, covering studies published from January 2018 to February 2024. A total of 157 met the predefined inclusion criteria. A critical analysis was performed regarding the clinical utility, implementation readiness, and limitations of these technologies, with particular attention to developmental variability and pediatric-specific safety requirements. Telehealth and mHealth tools were identified as effective solutions to improve accessibility and continuity of care by enabling remote consultations, real-time monitoring, and enhanced patient and family engagement. Precision medicine approaches demonstrated improved progression-free survival in selected high-risk pediatric populations, while AI-based tools supported diagnostic and prognostic decision-making. Despite these advances, the overall evidence remains heterogeneous, with limited high-quality randomized trials and scarce long-term cost-effectiveness evaluations. Ethical, infrastructural, and economic barriers continue to affect widespread implementation. A multidimensional and system-oriented approach is required to effectively integrate innovative technologies into real-world pediatric oncology and hematooncology settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.